You are here

Court Bans Manufacturing of Drugs by Alabama Company

FDA inspections found insanitary conditions

An Alabama company has been barred from making or selling drugs after FDA inspectors found that medications were produced under insanitary conditions and in violation of current good manufacturing practice requirements.

U.S. District Judge William H. Steele entered a consent decree of permanent injunction between the United States and Medistat RX LLC of Foley, Alabama; the company’s co-owners, Mark D. Acker and Timothy L. Fickling; and quality manager and pharmacist-in-charge V. Elaine Waller. The consent decree prohibits Medistat and those three individuals from manufacturing, holding, or distributing drugs until they comply with the Federal Food, Drug and Cosmetic Act (FD&C Act) and its regulations, in addition to other requirements.

Medistat manufactured and distributed purportedly sterile drug products that were adulterated because the drugs were made under insanitary conditions and in violation of current good manufacturing practice requirements under the FD&C Act. Drugs prepared, packed, or held under insanitary conditions may have been contaminated with filth or otherwise harmful if given to patients. Medistat also manufactured and distributed unapproved drugs and drugs that were misbranded because their labeling did not bear adequate directions for use, which are directions under which a consumer could use a drug safely and effectively for the purposes for which the drug is intended.

The FDA most recently inspected Medistat from August to September 2015, after receiving a complaint. Following the FDA inspection, because of a lack of sterility assurance for its purportedly sterile drug products, Medistat agreed to a voluntary nationwide recall of all lots of unexpired drug products produced for sterile use and distributed since November 1, 2014. Medistat also ceased sterile and nonsterile drug operations.

Previously, the FDA inspected Medistat in September 2014 and observed similar poor conditions and practices for sterile drug production. Despite assurances that Medistat was correcting its violations, the 2015 follow-up inspection revealed that the company had not implemented adequate corrective actions.

Medistat registered as an outsourcing facility in November 2014, but did not renew its registration the following year. The company notified the FDA it had permanently ceased operations in October 2015.

The complaint was filed by the U.S. Department of Justice on behalf of the FDA.

Source: FDA; July 6, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug